Chen X - Search Results

1

PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study.

Kuboki Y, Koyama T, Matsubara N, Naito Y, Kondo S, Harano K, Yonemori K, Yoh K, Gu Y, Mita T, Chen X, Ueda E, Yamamoto N, Doi T, Shimizu T. Kuboki Y, et al. Among authors: chen x. Cancer Med. 2024 Apr;13(8):e6980. doi: 10.1002/cam4.6980. Cancer Med. 2024. PMID: 38651187 Free PMC article. Clinical Trial.

2

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011).

Loh ML, Tasian SK, Rabin KR, Brown P, Magoon D, Reid JM, Chen X, Ahern CH, Weigel BJ, Blaney SM. Loh ML, et al. Among authors: chen x. Pediatr Blood Cancer. 2015 Oct;62(10):1717-24. doi: 10.1002/pbc.25575. Epub 2015 May 13. Pediatr Blood Cancer. 2015. PMID: 25976292 Free PMC article. Clinical Trial.

3

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.

Davis EJ, Martin-Liberal J, Kristeleit R, Cho DC, Blagden SP, Berthold D, Cardin DB, Vieito M, Miller RE, Hari Dass P, Orcurto A, Spencer K, Janik JE, Clark J, Condamine T, Pulini J, Chen X, Mehnert JM. Davis EJ, et al. Among authors: chen x. J Immunother Cancer. 2022 Oct;10(10):e004235. doi: 10.1136/jitc-2021-004235. J Immunother Cancer. 2022. PMID: 36316061 Free PMC article. Clinical Trial.

4

Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies.

Shi JG, Bowman KJ, Chen X, Maleski J, Leopold L, Yeleswaram S. Shi JG, et al. Among authors: chen x. J Clin Pharmacol. 2017 Jun;57(6):720-729. doi: 10.1002/jcph.855. Epub 2016 Dec 19. J Clin Pharmacol. 2017. PMID: 27990653 Clinical Trial.

5

Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.

Phillips TJ, Forero-Torres A, Sher T, Diefenbach CS, Johnston P, Talpaz M, Pulini J, Zhou L, Scherle P, Chen X, Barr PM. Phillips TJ, et al. Among authors: chen x. Blood. 2018 Jul 19;132(3):293-306. doi: 10.1182/blood-2017-10-812701. Epub 2018 Apr 25. Blood. 2018. PMID: 29695516 Free PMC article. Clinical Trial.

6

Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis.

Verstovsek S, Yeleswaram S, Hou K, Chen X, Erickson-Viitanen S. Verstovsek S, et al. Among authors: chen x. Hematol Oncol. 2018 Oct;36(4):701-708. doi: 10.1002/hon.2544. Epub 2018 Sep 11. Hematol Oncol. 2018. PMID: 30105794 Free PMC article. Clinical Trial.

7

Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib.

Barbour AM, Rockich K, Cimino E, Zhou G, Leonetti-Whalen C, Chen X, Yeleswaram S, Epstein N, Punwani N. Barbour AM, et al. Among authors: chen x. J Clin Pharmacol. 2021 Jul;61(7):954-960. doi: 10.1002/jcph.1814. Epub 2021 Jan 28. J Clin Pharmacol. 2021. PMID: 33434286

8

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.

Gong X, Chen X, Kuligowski ME, Liu X, Liu X, Cimino E, McGee R, Yeleswaram S. Gong X, et al. Among authors: chen x. Am J Clin Dermatol. 2021 Jul;22(4):555-566. doi: 10.1007/s40257-021-00610-x. Epub 2021 May 12. Am J Clin Dermatol. 2021. PMID: 33982267 Free PMC article. Clinical Trial.

9

Population pharmacokinetic and exposure-response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma.

Gong X, Akil A, Ndi A, Ji T, Liu X, Lovern M, Chen X. Gong X, et al. Among authors: chen x. CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1784-1794. doi: 10.1002/psp4.13064. Epub 2023 Nov 15. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37969064 Free PMC article.

10

Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B-cell malignancies: Results from the CITADEL-101 study.

Li J, Gong X, Liu X, Liu X, Szeto K, Chen X. Li J, et al. Among authors: chen x. Pharmacol Res Perspect. 2024 Apr;12(2):e1165. doi: 10.1002/prp2.1165. Pharmacol Res Perspect. 2024. PMID: 38407508 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

117,886 results

Search Page

Filters